Cheng et al. conducted a pooled analysis of data from randomized trials to assess the impact of age on the safety of anti-TNF therapy, showing that treatment of older patients with these agents did not increase the risk of serious adverse events or infections, compared with younger patients [278]. Here, TNF is linked to infection.